Farnesoid X receptor agonist INT-787 exhibits high intestinal localization

被引：0
|
作者：
Burkey, Jennifer [1 ]
Kansra, Sanjay [1 ]
Macchiarulo, Antonio [2 ]
Brouwer, Kenneth [3 ]
Adorini, Luciano [1 ]
Erickson, Mary [1 ]
Pellicciari, Roberto [4 ]
机构：
[1] Intercept Pharmaceut Inc, Morristown, NJ USA
[2] Univ Perugia, Dept Pharmaceut Sci, Perugia, Italy
[3] BioIVT, ADME TOX Div, Chapel Hill, NC USA
[4] TES Pharma Srl, Perugia, Italy
来源：
JOURNAL OF HEPATOLOGY | 2024年 / 80卷
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
THU-316
引用
收藏
页码：S126 / S127
页数：2
相关论文
共 50 条
  • [1] Farnesoid X receptor agonist INT-787 protects human liver organoids from alcohol-induced injury
    De Franco, Francesca
    Passeri, Daniela
    Kansra, Sanjay
    Adorini, Luciano
    Erickson, Mary
    Pellicciari, Roberto
    JOURNAL OF HEPATOLOGY, 2024, 80 : S124 - S125
  • [2] Increased hepatoprotective effects of the novel farnesoid X receptor agonist INT-787 versus obeticholic acid in a mouse model of nonalcoholic steatohepatitis
    Adorini, Luciano
    Rigbolt, Kristoffer
    Feigh, Michael
    Roth, Jonathan
    Erickson, Mary
    PLOS ONE, 2024, 19 (04):
  • [3] Tropifexor Farnesoid X receptor agonist Treatment of hepatobiliary and intestinal diseases
    Atieh, J.
    Camilleri, M.
    DRUGS OF THE FUTURE, 2021, 46 (10) : 803 - 811
  • [4] FXR AGONIST INT-787 INHIBITS INFLAMMATION, FIBROSIS, SENESCENCE, AND APOPTOSIS ARREST IN HUMAN CHOLANGIOCYTES MODELING PSC
    De Franco, Francesca
    Passeri, Daniela
    Kansra, Sanjay
    Adorini, Luciano
    Erickson, Mary
    Pellicciari, Roberto
    HEPATOLOGY, 2024, 80 : S1838 - S1839
  • [5] SAFETY, TOLERABILITY AND PHARMACOKINETICS OF ORAL INT-787, A NOVEL MODIFIED BILE ACID FXR AGONIST, IN HEALTHY VOLUNTEERS
    Capozza, Thomas
    Burkey, Jennifer
    Van De Wetering, Jerone
    Kerb, Reinhold
    Callahan, Jennifer
    Kryzhanovskaya, Ludmila
    Hughes, Kelly
    Erickson, Mary
    HEPATOLOGY, 2022, 76 : S1507 - S1508
  • [6] EDP-305, A Novel and Selective Farnesoid X Receptor Agonist, Exhibits high Potency and Efficacy In Vitro and In Vivo
    Li, Yang
    Chau, Mary D.
    Wang, Guoqiang
    Or, Yat Sun
    Jiang, Lijuan
    HEPATOLOGY, 2016, 64 : 767A - 767A
  • [7] EP-024297, A Novel and Selective Farnesoid X Receptor Agonist, Exhibits High Potency and Efficacy In Vitro and In Vivo
    Chau, Mary D.
    Li, Yang
    Wang, Guoqiang
    Or, Yat Sun
    Jiang, Lijuan
    HEPATOLOGY, 2016, 64 : 779A - 780A
  • [8] Protective Role of Farnesoid-X Receptor (FXR) Agonist in Intestinal Ischemia Reperfusion Injury.
    Ceulemans, Laurens J.
    Verbeke, Len
    Decuypere, Jean-Paul
    De Hertogh, Gert
    Farre, Ricard
    Lenaerts, Kaatje
    Nevens, Frederik
    Laleman, Wim
    Pirenne, Jacques
    TRANSPLANTATION, 2015, 99 : S49 - S50
  • [9] FIRST HUMAN EXPERIENCE WITH A SYNTHETIC FARNESOID X RECEPTOR (FXR) AGONIST - INT-7A7 (6α-ETHYLCHENODEOXYCHOLIC ACID)
    Shapiro, David
    March, Barrie
    Eliot, Lise
    duBois, Romeo
    Pruzanski, Mark
    HEPATOLOGY, 2009, 50 (04) : 770A - 771A
  • [10] Testosterone and farnesoid X receptor agonist INT-747 counteract high fat diet-induced bladder alterations in a rabbit model of metabolic syndrome
    Morelli, Annamaria
    Comeglio, Paolo
    Filippi, Sandra
    Sarchielli, Erica
    Cellai, Ilaria
    Vignozzi, Linda
    Yehiely-Cohen, Ravit
    Maneschi, Elena
    Gacci, Mauro
    Carini, Marco
    Adorini, Luciano
    Vannelli, Gabriella B.
    Maggi, Mario
    JOURNAL OF STEROID BIOCHEMISTRY AND MOLECULAR BIOLOGY, 2012, 132 (1-2): : 80 - 92
12345